Safety and Efficacy of 8-weeks Ledipasvir/Sofosbuvir Combination in Chronic Hepatitis C Genotype 4-Infected Patients

被引：0
|
作者：
Babatin, Mohamed [1 ]
Alghamdi, Abdullah S. [1 ]
Assiri, Abdullah [2 ]
Aleladi, Haziz [1 ]
Shoja, Hamad [1 ]
Mogharbel, Mohaammed [1 ]
Alsahafi, Ashwaq [1 ]
Mahalawi, Wadad [1 ]
Sanai, Faisl [3 ]
机构：
[1] King Fahad Gen Hosp, Jeddah, Saudi Arabia
[2] King Fahad Med City, Riyadh, Saudi Arabia
[3] King Abdul Aziz Med City, Jeddah, Saudi Arabia
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1537
引用
收藏
页码：821A / 821A
页数：1
相关论文
共 50 条
  • [1] Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
    Babatin, Mohammed A.
    AlGhamdi, Abdullah S.
    Assiri, Abdullah M.
    AlBiladi, Haziz
    AlOthmani, Hammad S.
    Mogharbe, Mohammed H.
    Mahallawi, Wedad
    Asselah, Tarik
    Sanai, Faisal M.
    [J]. SAUDI JOURNAL OF GASTROENTEROLOGY, 2019, 25 (01): : 55 - 60
  • [2] Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years
    Behairy, E. Behairy
    El-Araby, Hanaa A.
    El-Guindi, Mohamed A.
    Basiouny, Hosam-Eldin M.
    Fouad, Ola A.
    Ayoub, Bassam A.
    Marei, Ayman M.
    Sira, Mostafa M.
    [J]. JOURNAL OF PEDIATRICS, 2020, 219 : 106 - 110
  • [3] Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis
    Sanai, Faisal M.
    Altraif, Ibrahim H.
    Alswat, Khalid
    AlZanbagi, Adnan
    Babatin, Mohamed A.
    AlMousa, Abdallah
    Almutairi, Nawaf H.
    Aljawad, Mohammed S.
    Alghamdi, Abdullah S.
    Aljumah, Abdulrahman A.
    Alalwan, Abduljaleel M.
    Al-Hamoudi, Waleed K.
    Assiri, Abdullah M.
    Dahlan, Yaser
    Alsahafi, Ashwaq
    Alothmani, Hammad S.
    Alsaleemi, Mohammed S.
    Mousa, Waleed A.
    Albenmousa, Ali
    Awny, Abdelrahman
    Albiladi, Haziz
    Abdo, Ayman A.
    Alghamdi, Hamdan
    [J]. JOURNAL OF INFECTION, 2018, 76 (06) : 536 - 542
  • [4] Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting
    Zarebska-Michaluk, Dorota
    Jaroszewicz, Jerzy
    Jakub, Klapaczynski
    Sitko, Marek
    Garlicki, Aleksander
    Tudrujek, Magdalena
    Tomasiewicz, Krzysztof
    Belica-Wdowik, Teresa
    Baka-Cwierz, Barbara
    Pabjan, Pawel
    Lorenc, Beata
    Czauz-Andrzejuk, Agnieszka
    Olga, Tronina
    Krygier, Rafal
    Dobracka, Beata
    Orlowska, Iwona
    Krzysztof, Simon
    Dybowska, Dorota
    Halota, Waldemar
    Pawlowska, Malgorzata
    Citko, Jolanta
    Laurans, Lukasz
    Mazur, Wlodzimierz
    Piekarska, Anna
    Janczewska, Ewa
    Socha, Lukasz
    Wawrzynowicz-Syczewska, Marta
    Zbigniew, Deron
    Berak, Hanna
    Andrzej, Horban
    Flisiak, Robert
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E249 - E250
  • [5] Efficacy and safety of sofosbuvir and ledipasvir in the treatment of elderly Japanese patients with hepatitis C genotype 1 infected
    Nagata, Kenji
    Hasuike, Satoru
    Takaishi, Yuuka
    Yamada, Yuuri
    Tsuchimochi, Mai
    Nakamura, Kennichi
    Shimoda, Kazuya
    Sueta, Mitsue
    Kusumoto, Kazunori
    Ochiai, Toshimasa
    Kato, Junya
    Komada, Naoto
    Oozono, Yoshinori
    Hirono, Shuichi
    Kuroki, Kazuo
    Shigehira, Masafumi
    Shimoda, Kazuya
    [J]. HEPATOLOGY, 2016, 64 : 953A - 953A
  • [6] Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection
    Gane, Edward J.
    Hyland, Robert H.
    Yang, Yin
    Svarovskaia, Evguenia
    Stamm, Luisa M.
    Brainard, Diana M.
    McHutchison, John G.
    Stedman, Catherine A. M.
    [J]. GASTROENTEROLOGY, 2017, 152 (06) : 1366 - 1371
  • [7] Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection
    Ahmed, Ossama A.
    Kaisar, Hany H.
    Badawi, Rehab
    Hawash, Nehad
    Samir, Hossam
    Shabana, Sherif S. T.
    Fouad, Mohamed Hassan A.
    Rizk, Fatma H.
    Khodeir, Samy A.
    Abd-Elsalam, Sherief
    [J]. INFECTION AND DRUG RESISTANCE, 2018, 11 : 295 - 298
  • [8] High Efficacy of Ledipasvir/Sofosbuvir Combination With or Without Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4-infected Compensated and Decompensated Cirrhosis Patients: Real Life Data From Saudi Arabia
    Sanai, Faisal M.
    AlZanbagi, Adnan
    Babatin, Mohamed A.
    Alghamdi, Abdullah S.
    AlGhamdi, Hamdan
    Alswat, Kahlid
    Aljumah, Abdulrahman A.
    Al Alwan, Abduljaleel M.
    Abdo, Ayman
    Al-Hamoudi, Waleed K.
    Alaseeri, Abdullah
    Dahlan, Yaser
    Alsahafi, Ashwaq
    Alothmani, Hammad S.
    Albiladi, Haziz
    Altraif, Ibrahim H.
    [J]. HEPATOLOGY, 2016, 64 : 478A - 479A
  • [9] Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection
    Abergel, Armand
    Metivier, Sophie
    Samuel, Didier
    Jiang, Deyuan
    Kersey, Kathryn
    Pang, Phillip S.
    Svarovskaia, Evguenia
    Knox, Steven J.
    Loustaud-Ratti, Veronique
    Asselah, Tarik
    [J]. HEPATOLOGY, 2016, 64 (04) : 1049 - 1056
  • [10] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    [J]. CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
12345